Dasatinib May Override F317L BCR-ABL Kinase Domain Mutation in Patients with Chronic Myeloid Leukemia

Eskazan, Ahmet EmreSoysal, Teoman2024-04-242024-04-2420131300-77771308-5263https://doi.org/10.4274/Tjh.2012.0013https://hdl.handle.net/11468/19689[Abstract Not Available]eninfo:eu-repo/semantics/openAccess[No Keyword]Dasatinib May Override F317L BCR-ABL Kinase Domain Mutation in Patients with Chronic Myeloid LeukemiaDasatinib May Override F317L BCR-ABL Kinase Domain Mutation in Patients with Chronic Myeloid LeukemiaLetter302211213WOS:0003209725000202438578910.4274/Tjh.2012.0013Q4